Intercept Pharmaceuticals, Immunomedics Inc., and MannKind Corp. Could Be Big Movers in Health Care Today

Today's morning movers in the health care sector.

Jan 10, 2014 at 9:09AM

Good morning, fellow Fools! Let's check in on the top stories in health care this morning.

Intercept continues to soar
Intercept Pharmaceuticals (NASDAQ:ICPT) is up big again this morning after Citigroup set a $400-a-share price target on the company today, despite the 281% jump yesterday. This upgrade represents a potential 60% upside remaining in the stock.

To recap yesterday's events, shares of Intercept soared after the company's experimental liver disease drug, obeticholic acid, showed such a strong benefit to patients compared to placebo that the trial was stopped early. Experts believe the drug could see peak sales of around $5 billion a year as a treatment for nonalcoholic steatohepatitis, or NASH, if approved by the U.S. Food and Drug Administration. Currently, there are no approved drugs for the disease, even though it is a leading cause of liver transplants in the U.S.

Should you take a closer look at Intercept? It's important to remember that these are midstage results, meaning the drug is about two-thirds of the way through the normal clinical trial process. That said, the results were so impressive and there is such an unmet medical need with NASH that it's highly likely Intercept will seek accelerated approval.

My take is that the market believes that accelerated approval is forthcoming based on these stellar results. Nonetheless, you need to realize that there is a real risk of a rejection from the FDA for accelerated approval, if the company goes that route. Just ask Sarepta Therapeutics. Put simply, nothing is a given with the FDA.

Even so, there is a better than average chance that Intercept's drug is approved sooner rather than later. In that case, today's share price could look cheap if the drug lives up to the hype. So my take is that Intercept does warrant a closer look, even after yesterday's monstrous rally.

Immunomedics continues to rally on clinical progress
Monoclonal antibody specialist Immunomedics (NASDAQ:IMMU) is up big in premarket this morning after announcing the start of a late-stage trial for its experimental pancreatic cancer therapy clivatuzumab. The trial will enroll up to 440 patients with metastatic pancreatic cancer, with enrollment expected to be completed by mid-2015. 

Is this story worth checking out? I believe so. The company's approach is similar to Seattle Genetics and Roche's approved antibody drug conjugates that are top-line cancer therapies, and clivatuzumab would be the first such therapy for pancreatic cancer. What's key to understand is that pancreatic cancer is notoriously difficult to treat, especially when patients fail frontline treatments. So there is an unmet medical need in this area that clivatuzumab could help to fill.

With that said, you need to understand that Immunomedics is a developmental-stage company that relies mostly on dilution for funding, and this trial won't be completed anytime soon. So you might want to wait to see how this plays out before jumping in right now. 

MannKind falling back to Earth
Shares of MannKind (NASDAQ:MNKD) are pulling back a fair amount in premarket this morning after yesterday's 18% jump. MannKind soared yesterday after word leaked that an FDA Advisory Committee would possibly review the company's lead clinical candidate Afrezza on April 1 of this year. The review is expected to be completed no later than April 15.

Afrezza is an inhalable, ultra-fast-acting insulin product that could dominate the insulin delivery market if approved. Last year, Afrezza completed two late-stage trials requested by the FDA that will be the main focus of the upcoming regulatory review.

So, what's my take? I think Afrezza will get approved this time around based on the strength of its late-stage trial results. In my view, the real question is whether or not the drug can gain market share against the likes of Novo Nordisk's and Eli Lilly's injectable pens that deliver fast-acting insulin. Overall, I am cautiously optimistic that MannKind will finally deliver on the promise of an inhalable insulin product that customers actually want to use. So you might want to keep tabs on this compelling story going forward. 

These three stocks might beat Intercept Pharmaceuticals, Immunomedics, and MannKind this year
 It's no secret that investors tend to be impatient with the market, but the best investment strategy is to buy shares in solid businesses and keep them for the long term. In the special free report "3 Stocks That Will Help You Retire Rich," The Motley Fool shares investment ideas and strategies that could help you build wealth for years to come. Click here to grab your free copy today.

Fool contributor George Budwell has no position in any stocks mentioned. The Motley Fool recommends Seattle Genetics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers